MX2012003220A - Formulaciones farmaceuticas que comprenden 9-cis-retinil esteres en un vehiculo de lipido. - Google Patents
Formulaciones farmaceuticas que comprenden 9-cis-retinil esteres en un vehiculo de lipido.Info
- Publication number
- MX2012003220A MX2012003220A MX2012003220A MX2012003220A MX2012003220A MX 2012003220 A MX2012003220 A MX 2012003220A MX 2012003220 A MX2012003220 A MX 2012003220A MX 2012003220 A MX2012003220 A MX 2012003220A MX 2012003220 A MX2012003220 A MX 2012003220A
- Authority
- MX
- Mexico
- Prior art keywords
- cis
- pharmaceutical formulations
- lipid vehicle
- retinyl esters
- retinyl
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/07—Retinol compounds, e.g. vitamin A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Emergency Medicine (AREA)
- Dermatology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dispersion Chemistry (AREA)
- Ophthalmology & Optometry (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Nutrition Science (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Non-Alcoholic Beverages (AREA)
Abstract
Se describen formulaciones farmacéuticas que comprenden 9-cis-retinil ésteres en un vehículo de lípido como terapias de reemplazo de retinoide para tratar degeneraciones retinales en seres humanos.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US24274109P | 2009-09-15 | 2009-09-15 | |
PCT/US2009/059126 WO2011034551A2 (en) | 2009-09-15 | 2009-09-30 | Pharmaceutical formulations comprising 9-cis-retinyl esters in a lipid vehicle |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2012003220A true MX2012003220A (es) | 2012-08-03 |
Family
ID=43242391
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2012003220A MX2012003220A (es) | 2009-09-15 | 2009-09-30 | Formulaciones farmaceuticas que comprenden 9-cis-retinil esteres en un vehiculo de lipido. |
Country Status (14)
Country | Link |
---|---|
US (3) | US20120178806A1 (es) |
JP (2) | JP5663025B2 (es) |
KR (1) | KR101710505B1 (es) |
CN (1) | CN102612375B (es) |
AR (1) | AR076184A1 (es) |
AU (1) | AU2009352678B2 (es) |
BR (1) | BR112012005905A2 (es) |
CA (1) | CA2774168C (es) |
HK (1) | HK1170158A1 (es) |
IN (1) | IN2012DN02466A (es) |
MX (1) | MX2012003220A (es) |
MY (1) | MY174082A (es) |
RU (1) | RU2546005C2 (es) |
WO (1) | WO2011034551A2 (es) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR112012005905A2 (pt) | 2009-09-15 | 2020-02-18 | Qlt Inc. | Formulação farmacêutica, método para tratar a amaurose congênita de leber em um indivíduo humano, e, método para tratar um indivíduo |
US9173856B2 (en) * | 2010-04-19 | 2015-11-03 | Qlt Inc. | Therapeutic regimen and methods for treating or ameliorating visual disorders associated with an endogenous retinoid deficiency |
KR102029657B1 (ko) * | 2011-06-08 | 2019-10-08 | 닛토덴코 가부시키가이샤 | 표적 약물 전달체 및 siRNA 활성을 증가시키는 화합물 |
BR112014021602A2 (pt) | 2012-03-01 | 2021-06-08 | Quadra Logic Tech Inc | uso, kit e derivado de retinal sintético para melhorar a função visual em distúrbios visuais associados com a deficiência de produção endógena de retinóide |
EP3317372B1 (en) | 2015-06-30 | 2018-10-17 | Unilever NV | Composition containing vegetable oil, caramel and phenolic compounds |
MY194096A (en) * | 2016-04-28 | 2022-11-11 | Spark Therapeutics Inc | Relative potency assay for viral vector encoding isomerhydrolases |
HUE064808T2 (hu) | 2016-11-17 | 2024-04-28 | Univ Of Debrecen | Prekurzor vegyületek az A5-vitamin útvonal retinoidjainak elõállítására és azok alkalmazása |
CN116056691A (zh) * | 2020-06-09 | 2023-05-02 | 典晶生物医药科技(苏州)有限公司 | 使用每日低剂量的类视黄醇化合物治疗视觉障碍的方法 |
Family Cites Families (62)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3196078A (en) | 1962-01-30 | 1965-07-20 | Ortho Pharma Corp | Process for combating retinits pigmentosa |
US3517067A (en) | 1964-02-11 | 1970-06-23 | Eastman Kodak Co | Syntheses of quaternary phosphonium salts |
DE2300107C2 (de) | 1973-01-03 | 1982-03-11 | Basf Ag, 6700 Ludwigshafen | Vitamin A-Säureanilid-4-carbonsäureäthylester, Verfahren zu seiner Herstellung und diesen enthaltende Zubereitungen |
CH590222A5 (es) | 1973-08-21 | 1977-07-29 | Hoffmann La Roche | |
US4022913A (en) * | 1973-09-13 | 1977-05-10 | Hoffmann-La Roche Inc. | High potency vitamin A compositions |
DE2456959A1 (de) | 1974-12-03 | 1976-06-16 | Basf Ag | 4-(e)- und 4-(z)-7-methyl-9-(2,6,6trimethyl-1-cyclohexen-1-yl)-nona-2,4,6,8tetraencarbonsaeure, ihre derivate und diese enthaltende zubereitungen |
US4532133A (en) * | 1983-05-24 | 1985-07-30 | Basf Wyandotte Corporation | Low temperature stable, emulsifiable vitamin A concentrates |
CA1282326C (en) | 1984-12-14 | 1991-04-02 | Paul J. Jarosz | Pharmaceutical composition containing 13-cis vitamin a acid as the active ingredient |
JPS61275266A (ja) | 1985-05-28 | 1986-12-05 | Taisho Pharmaceut Co Ltd | レチノイド誘導体 |
CZ282548B6 (cs) | 1992-01-22 | 1997-08-13 | F. Hoffmann-La Roche Ag | Farmaceutický přípravek |
US5310764A (en) | 1992-05-08 | 1994-05-10 | Steven Baranowitz | Treatment of age related macular degeneration with beta-carotene |
JPH06340525A (ja) | 1993-06-02 | 1994-12-13 | Lion Corp | 安定な低眼刺激性ビタミンa類可溶化点眼剤 |
CA2185699A1 (en) | 1994-04-04 | 1995-10-12 | William R. Freeman | Use of phosphonylmethoxyalkyl nucleosides for the treatment of raised intraocular pressure |
RU2106843C1 (ru) | 1994-06-29 | 1998-03-20 | Красноярская государственная медицинская академия | Способ лечения близорукости |
JPH08198746A (ja) | 1995-01-18 | 1996-08-06 | Lion Corp | 可溶化点眼剤 |
US5837728A (en) | 1995-01-27 | 1998-11-17 | Molecular Design International | 9-cis retinoic acid esters and amides and uses thereof |
US5489611A (en) | 1995-02-10 | 1996-02-06 | Warner-Lambert Company | Method for lowering plasma levels of lipoprotein (a) |
US5620970A (en) | 1995-06-05 | 1997-04-15 | Alcon Laboratories, Inc. | Topical ophthalmic carbonic anhydrase inhibitor formulations |
EP0839029A1 (en) | 1995-07-20 | 1998-05-06 | PHARMACIA & UPJOHN COMPANY | Stable clear solutions of non-steroidal anti-inflammatory drugs for incorporation into gelatin capsules |
US5716627A (en) | 1996-04-25 | 1998-02-10 | Elizabeth Arden Co., Division Of Conopco, Inc. | Skin care compositions containing fatty acid amides, azoles, and retinol or retinyl ester |
US5744148A (en) * | 1996-09-20 | 1998-04-28 | Chesebrough-Pond's Usa Co., Division Of Conopco, Inc. | Stabilization of an unstable retinoid in oil-in-water emulsions for skin care compositions |
EP0908179A1 (en) | 1997-08-23 | 1999-04-14 | Werner Bollag | Treatment of cell-mediated immune diseases |
ZA989513B (en) | 1997-10-21 | 1999-04-21 | Alcon Lab Inc | Compositions containing histamine H2 agonists and methods of use in treating dry eye |
US6391924B1 (en) | 1997-12-10 | 2002-05-21 | Hampar Karageozian | Taurine derivatives useable in the treatment of ophthalmic disorders |
US6552009B2 (en) | 1998-07-16 | 2003-04-22 | Gentrix Llc | Compositions and methods of treating abnormal cell proliferation |
US6267985B1 (en) * | 1999-06-30 | 2001-07-31 | Lipocine Inc. | Clear oil-containing pharmaceutical compositions |
US6372463B1 (en) | 1999-05-06 | 2002-04-16 | The President & Fellows Of Harvard College | Mutations in nucleic acid molecules encoding 11-CIS retinol dehydrogenase, the mutated proteins, and uses thereof |
US6300328B1 (en) | 1999-08-06 | 2001-10-09 | Alcon Universal Ltd. | Selective inhibitors of adenosine monophosphate deaminase for the treatment of optic nerve and retinal damage |
US20020028849A1 (en) | 2000-04-18 | 2002-03-07 | Godkin James D. | Use of retinol in assisted-reproduction protocols |
US6696069B2 (en) | 2000-06-30 | 2004-02-24 | Unilever Home & Personal Care Usa, Division Of Conopco, Inc. | Skin care cosmetic compositions containing phosphates and/or sulfates of branched alcohols and/or ethoxylates thereof |
US20040077604A1 (en) * | 2001-12-19 | 2004-04-22 | Lenard Lichtenberger | Method and compositions employing formulations of lecithin oils and nsaids for protecting the gastrointestinal tract and providingenhanced therapeutic activity |
US20020142016A1 (en) * | 2000-12-28 | 2002-10-03 | Granger Stewart Paton | Stable skin care product containing a retinoid and a retinoid booster system in a dual compartment package |
WO2002055540A1 (en) | 2001-01-11 | 2002-07-18 | Chebigen Inc. | New retinol derivatives, the method of preparations and the uses thereof |
WO2002082904A2 (en) | 2001-04-13 | 2002-10-24 | The Trustees Of The University Of Pennsylvania | Method of treating or retarding the development of blindness |
ITMI20012366A1 (it) * | 2001-11-09 | 2003-05-09 | Farmatron Ltd | Sistemi terapeutici stabilizzati a rilascio immediato e/o modificato per la somministrazione orale di principi attivi e/o eccipienti e/o ali |
EP1450791A1 (en) * | 2001-11-30 | 2004-09-01 | Kinetek Pharmaceuticals, Inc. | Hydrazonopyrazole derivatives and their use as therapeutics |
CA2474154A1 (en) | 2002-01-18 | 2003-07-24 | Tatton Technologies, Llc. | Methods for treating eye disorders |
US20030215413A1 (en) | 2002-03-22 | 2003-11-20 | L'oreal | Compositions containing stabilized retinoid |
US20040097587A1 (en) | 2002-03-27 | 2004-05-20 | Arbiser Jack L | Compositions and methods of treatment of ulcerating diseases, burns, and related conditions |
TW200305398A (en) | 2002-03-29 | 2003-11-01 | Maxim Pharm Inc | Use of ROM production and release inhibitors to treat and prevent intraocular damage |
JP3854524B2 (ja) | 2002-04-01 | 2006-12-06 | ピアス株式会社 | 油溶性成分安定化組成物及びその組成物を配合した化粧料、並びに油溶性成分の安定化方法 |
EP1527774A1 (en) | 2003-11-03 | 2005-05-04 | Basilea Pharmaceutica AG | New formulation for retinoid-containing soft gelatin capsules |
US20060281821A1 (en) | 2003-03-14 | 2006-12-14 | Krzysztof Palczewski | Retinoid replacements and opsin agonists and methods for the use thereof |
EP1510133A1 (en) | 2003-09-01 | 2005-03-02 | Belovo S.A., Egg Science & Technology | Balanced oil composition |
EP1662979B1 (en) | 2003-09-04 | 2016-03-02 | The Uab Research Foundation | Method and apparatus for the detection of impaired dark adaptation |
US7706863B2 (en) | 2004-01-21 | 2010-04-27 | University Of Washington | Methods for assessing a physiological state of a mammalian retina |
US20080176952A1 (en) | 2004-02-17 | 2008-07-24 | Rando Robert R | Management of Ophthalmologic Disorders, Including Macular Degeneration |
CA2601278C (en) | 2004-03-17 | 2014-06-10 | Lars Michael Larsen | Prevention of retinopathy by inhibition of the visual cycle |
KR101337321B1 (ko) | 2004-06-18 | 2013-12-06 | 유니버시티 오브 워싱톤 | 시각 이상 치료를 위한 레티날 유도체 및 이를 이용하기위한 방법 |
ATE404188T1 (de) | 2004-06-23 | 2008-08-15 | Sirion Therapeutics Inc | Verfahren und zusammensetzungen zur behandlung von augenerkrankungen mit retinyl-derivaten |
US20060240098A1 (en) * | 2004-07-14 | 2006-10-26 | Aphios Corporation | Formulations for hyperforin-enriched hypericum fractions |
JP2008515778A (ja) | 2004-08-18 | 2008-05-15 | シリオン セラピューティクス, インコーポレイテッド | 眼の状態を13−シス−レチニル誘導体で処置するための組み合わせ方法、組成物および治療 |
WO2006039551A2 (en) | 2004-09-30 | 2006-04-13 | The Regents Of The University Of California | Local administration of retinoids to treat deficiencies in dark adaptation |
US20060177392A1 (en) | 2005-02-10 | 2006-08-10 | William Walden | Oil-based composition for acne |
AU2006311818B9 (en) | 2005-11-07 | 2013-05-16 | Murty Pharmaceuticals, Inc | Improved delivery of tetrahydrocannabinol |
US8202541B2 (en) * | 2006-02-07 | 2012-06-19 | U.S. Nutraceuticals, LLC | Dietary supplement composition for blood lipid health |
AU2007277032A1 (en) * | 2006-07-27 | 2008-01-31 | University Of Florida Research Foundation, Inc. | Opsin stabilizing compounds and methods of use |
CA2674822C (en) | 2007-01-15 | 2017-08-01 | Chongxi Yu | Positively charged water-soluble prodrugs of retinoids and retinoid-like compounds with very high skin penetration rates |
EP2187880B1 (en) | 2007-09-12 | 2013-12-18 | The Trustees of Columbia University in the City of New York | Compositions and methods for treating macular degeneration |
RU2565448C2 (ru) | 2008-02-11 | 2015-10-20 | Юниверсити Оф Вашингтон | Способы лечения и предупреждения обусловленной возрастом дисфункции сетчатки |
BR112012005905A2 (pt) * | 2009-09-15 | 2020-02-18 | Qlt Inc. | Formulação farmacêutica, método para tratar a amaurose congênita de leber em um indivíduo humano, e, método para tratar um indivíduo |
US9173856B2 (en) | 2010-04-19 | 2015-11-03 | Qlt Inc. | Therapeutic regimen and methods for treating or ameliorating visual disorders associated with an endogenous retinoid deficiency |
-
2009
- 2009-09-30 BR BR112012005905-0A patent/BR112012005905A2/pt active Search and Examination
- 2009-09-30 AU AU2009352678A patent/AU2009352678B2/en active Active
- 2009-09-30 CA CA2774168A patent/CA2774168C/en active Active
- 2009-09-30 MX MX2012003220A patent/MX2012003220A/es active IP Right Grant
- 2009-09-30 JP JP2012529727A patent/JP5663025B2/ja active Active
- 2009-09-30 US US13/496,113 patent/US20120178806A1/en not_active Abandoned
- 2009-09-30 CN CN200980162279.0A patent/CN102612375B/zh active Active
- 2009-09-30 KR KR1020127009638A patent/KR101710505B1/ko active IP Right Grant
- 2009-09-30 WO PCT/US2009/059126 patent/WO2011034551A2/en active Application Filing
- 2009-09-30 RU RU2012114791/15A patent/RU2546005C2/ru active
-
2010
- 2010-03-31 AR ARP100101113A patent/AR076184A1/es not_active Application Discontinuation
- 2010-09-30 MY MYPI2012001162A patent/MY174082A/en unknown
-
2012
- 2012-03-21 IN IN2466DEN2012 patent/IN2012DN02466A/en unknown
- 2012-10-30 HK HK12110875.5A patent/HK1170158A1/zh unknown
-
2014
- 2014-07-07 JP JP2014139741A patent/JP2014185185A/ja not_active Withdrawn
-
2016
- 2016-09-23 US US15/274,257 patent/US10130606B2/en active Active
-
2018
- 2018-10-12 US US16/158,738 patent/US10736865B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
WO2011034551A2 (en) | 2011-03-24 |
CN102612375B (zh) | 2016-01-27 |
IN2012DN02466A (es) | 2015-08-21 |
BR112012005905A2 (pt) | 2020-02-18 |
US20120178806A1 (en) | 2012-07-12 |
US20190183835A1 (en) | 2019-06-20 |
HK1170158A1 (zh) | 2013-02-22 |
CA2774168A1 (en) | 2011-03-24 |
AU2009352678A1 (en) | 2012-04-05 |
AR076184A1 (es) | 2011-05-26 |
US20170007565A1 (en) | 2017-01-12 |
KR20120064707A (ko) | 2012-06-19 |
WO2011034551A3 (en) | 2011-12-15 |
RU2546005C2 (ru) | 2015-04-10 |
KR101710505B1 (ko) | 2017-02-27 |
JP2013504617A (ja) | 2013-02-07 |
CN102612375A (zh) | 2012-07-25 |
US10736865B2 (en) | 2020-08-11 |
JP2014185185A (ja) | 2014-10-02 |
RU2012114791A (ru) | 2013-10-27 |
MY174082A (en) | 2020-03-09 |
JP5663025B2 (ja) | 2015-02-04 |
AU2009352678B2 (en) | 2015-05-21 |
US10130606B2 (en) | 2018-11-20 |
CA2774168C (en) | 2021-02-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2012003220A (es) | Formulaciones farmaceuticas que comprenden 9-cis-retinil esteres en un vehiculo de lipido. | |
EP2493478B8 (en) | Concentrated therapeutic phospholipid compositions | |
WO2009154463A3 (en) | Butyrate as a medicament to improve visceral perception in humans | |
MX2013008850A (es) | Composiciones y metodos para tratar enfermedades cardiovasculares. | |
MY188956A (en) | Processes for producing lipids | |
IN2014CN02616A (es) | ||
MX370264B (es) | Combinacion farmaceutica para uso en el control glucemico en pacientes con diabetes de tipo 2. | |
EP2654695B8 (en) | Enzymatic peracid generation for use in oral care products | |
MY156518A (en) | Borinic compositions | |
MX356728B (es) | Combinación farmacéutica para usar en el tratamiento de pacientes que padecen diabetes de tipo 2. | |
EP2676172A4 (en) | Direct generation semiconductor ircm laser system | |
IN2012DN03807A (es) | ||
WO2012106427A3 (en) | Methods for treating diabetic foot ulcers | |
MX357284B (es) | Compuestos de quinona para tratar enfermedades mediadas por ape1. | |
EP2656837A4 (en) | LIPID NANOPARTICLES FOR THE TREATMENT OF OCULAR DISEASES | |
EP2655607A4 (en) | METHOD AND COMPOSITIONS FOR PRODUCING ACTIVE VITAMIN K-DEPENDENT PROTEINS | |
EP2785335B8 (en) | Methods and pharmaceutical compositions for the treatment of darier disease | |
AU2012345659A8 (en) | Acamprosate formulations, methods of using the same, and combinations comprising the same | |
WO2012078816A9 (en) | Proteins that efficiently generate singlet oxygen | |
WO2012027601A9 (en) | Methods targeting mir-33 micrornas for regulating lipid metabolism | |
PL2648666T3 (pl) | Urządzenie laserowe, zwłaszcza do okulistycznej chirurgii laserowej | |
EP2502897A4 (en) | METHOD FOR PRODUCING AN OPTICALLY ACTIVE BICYCLO [3.1.0-] HEXENE DERIVATIVE USING OXYGEN | |
UA69863U (ru) | Способ коррекции возрастных изменений кожи у женщин | |
UA65175U (en) | Method of uranostaphyloplasty | |
MX2011011128A (es) | Un producto lacteo bajo en colesterol para uso como un medicamento. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |